- Mitiglinide
-
Mitiglinide Systematic (IUPAC) name (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid Clinical data AHFS/Drugs.com International Drug Names Pregnancy cat. ? Legal status ? Routes oral Identifiers CAS number 207844-01-7 ATC code A10BX08 PubChem CID 121891 DrugBank DB01252 ChemSpider 108739 UNII D86I0XLB13 KEGG D01854 Chemical data Formula C19H25NO3 Mol. mass 315.41 g/mol SMILES eMolecules & PubChem (what is this?) (verify)
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.[1]
Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Contents
Pharmacology
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.
Dosage
Mitiglinide is delivered in tablet form.
References
- ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. http://www.informapharmascience.com/doi/abs/10.1517/14656566.9.15.2691.
External links
- Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.
Oral anti-diabetic drugs and Insulin analogs (A10) Insulin K+ ATPMeglitinides/"glinides"GLP-1 analogsfast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec†) • inhalable Exubera‡Other Amylin analogSGLT2 inhibitorsOtherBenfluorex‡ • Tolrestat‡Categories:- Meglitinides
- Isoindoles
- Amides
Wikimedia Foundation. 2010.